153 related articles for article (PubMed ID: 37563017)
21. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen QN; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
Lancet Oncol; 2024 May; 25(5):e193-e204. PubMed ID: 38697165
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
23. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
Zalay O; Mehra P; Pereira I; Malone J; Malone S
World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
[TBL] [Abstract][Full Text] [Related]
24. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
Napieralska A; Miszczyk L; Stapor-Fudzinska M
Neoplasma; 2016; 63(2):304-12. PubMed ID: 26774153
[TBL] [Abstract][Full Text] [Related]
25. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.
All S; Garant A; Hannan R
Semin Radiat Oncol; 2021 Jul; 31(3):227-234. PubMed ID: 34090649
[TBL] [Abstract][Full Text] [Related]
27. Life-threatening hemoptysis in patients with metastatic kidney cancer.
Patel VM; Elias R; Asokan A; Sharma A; Christie A; Pedrosa I; Chiu H; Reznik S; Hannan R; Timmerman R; Brugarolas J
Clin Genitourin Cancer; 2023 Aug; 21(4):497-506. PubMed ID: 37045713
[TBL] [Abstract][Full Text] [Related]
28. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.
Franzese C; Franceschini D; Di Brina L; DʼAgostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M
J Urol; 2019 Jan; 201(1):70-75. PubMed ID: 30577391
[TBL] [Abstract][Full Text] [Related]
29. Superior target delineation for stereotactic body radiotherapy of bone metastases from renal cell carcinoma on MRI compared to CT.
Prins FM; van der Velden JM; Gerlich AS; Kotte ANTJ; Eppinga WSC; Kasperts N; Verlaan JJ; Pameijer FA; Kerkmeijer LGW
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S147-S154. PubMed ID: 28866897
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases.
Kothari G; Louie AV; Pryor D; Vela I; Lo SS; Teh BS; Siva S
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S17. PubMed ID: 28917255
[TBL] [Abstract][Full Text] [Related]
31. The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer.
Dohopolski M; Hannan R; Wardak Z; Hammers H; Garant A
Cancer J; 2020; 26(5):448-459. PubMed ID: 32947313
[TBL] [Abstract][Full Text] [Related]
32. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
Napieralska A; Miszczyk L; Stąpór-Fudzińska M
Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
35. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
36. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
[TBL] [Abstract][Full Text] [Related]
37. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial.
Mercier C; Claessens M; Buys MSc A; Gryshkevych S; Billiet C; Joye I; Van Laere S; Vermeulen P; Meijnders P; Löfman F; Poortmans P; Dirix L; Verellen D; Dirix P
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1195-1205. PubMed ID: 33307151
[TBL] [Abstract][Full Text] [Related]
39. Global management of brain metastasis from renal cell carcinoma.
Pierrard J; Tison T; Grisay G; Seront E
Crit Rev Oncol Hematol; 2022 Mar; 171():103600. PubMed ID: 35063636
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease.
Alongi F; Arcangeli S; Triggiani L; Mazzola R; Buglione di Monale E Bastia M; Fersino S; Baiguini A; Jereczek-Fossa BA; Magrini SM;
Crit Rev Oncol Hematol; 2017 Sep; 117():48-56. PubMed ID: 28807235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
